Mixed Epilepsy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mixed epilepsy. 7 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
7
Active US patents
55/100
Avg vulnerability
—
Annual revenue covered

Originators in Mixed Epilepsy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis AG (originally Geigy) 7 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mixed epilepsy. Each bar = one year. Y-axis scaled to peak year (3 patents).

2
28
3
29
1
33
1
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9629797 Tegretol method of use 75 2028-11-10
9770407 Tegretol formulation 55 2028-11-10
9750822 Tegretol formulation 55 2029-03-13
8410077 Tegretol formulation 55 2029-03-13
7635773 Tegretol formulation 55 2029-03-13
11529357 Tegretol formulation 50 2040-01-31
9493582 Tegretol formulation 42 2033-02-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9493582 Tegretol formulation 42 2033-02-27
11529357 Tegretol formulation 50 2040-01-31
9750822 Tegretol formulation 55 2029-03-13
8410077 Tegretol formulation 55 2029-03-13
7635773 Tegretol formulation 55 2029-03-13
9770407 Tegretol formulation 55 2028-11-10
9629797 Tegretol method of use 75 2028-11-10

Related